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Abstract
Background: Weight loss in overweight or obese breast cancer patients is associated with an improved prognosis
for long term survival. However, it is not clear whether the macronutrient composition of the chosen weight loss
dietary plan imparts further prognostic benefit. A study protocol is presented for a dietary intervention to
investigate the effects of weight loss dietary patterns that vary markedly in fat and carbohydrate contents on
biomarkers of exposure to metabolic processes that may promote tumorigenesis and that are predictive of long
term survival. The study will also determine how much weight must be lost for biomarkers to change in a
favorable direction.
Methods/Design: Approximately 370 overweight or obese postmenopausal breast cancer survivors (body mass
index: 25.0 to 34.9 kg/m
2) will be accrued and assigned to one of two weight loss intervention programs or a non-
intervention control group. The dietary intervention is implemented in a free living population to test the two
extremes of popular weight loss dietary patterns: a high carbohydrate, low fat diet versus a low carbohydrate, high
fat diet. The effects of these dietary patterns on biomarkers for glucose homeostasis, chronic inflammation, cellular
oxidation, and steroid sex hormone metabolism will be measured. Participants will attend 3 screening and dietary
education visits, and 7 monthly one-on-one dietary counseling and clinical data measurement visits in addition to
5 group visits in the intervention arms. Participants in the control arm will attend two clinical data measurement
visits at baseline and 6 months. The primary outcome is high sensitivity C-reactive protein. Secondary outcomes
include interleukin-6, tumor necrosis factor-a, insulin-like growth factor-1 (IGF), IGF binding protein-3, 8-isoprostane-
F2-alpha, estrone, estradiol, progesterone, sex hormone binding globulin, adiponectin, and leptin.
Discussion: While clinical data indicate that excess weight for height is associated with poor prognosis for long
term survival, little attention is paid to weight control in the clinical management of breast cancer. This study will
provide information that can be used to answer important patient questions about the effects of dietary pattern
and magnitude of weight loss on long term survival following breast cancer treatment.
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Breast cancer is the most common form of cancer in
women in the United States [1] and one of the top ten
causes of death [2]. Recent estimates show age-adjusted
incidence rate is 123.8 per 100,000 women per year [3].
Body fat is now established as being causally related to
postmenopausal breast cancer [1,4-8], with overweight
or obese women having almost twice the rates of cancer
recurrence and up to 1.5 times the risk of death from
breast cancer compared to women in the healthy weight
range [1,4-7,9-16]. These are alarming findings since the
majority of women in the United States are now over-
weight or obese (i.e. body weight (kg)/height (m
2)>
24.9) [17]. This situation is compounded by the fact that
weight gain is common post-diagnosis [18,19].
Studies have shown that losing body weight is protec-
tive against breast cancer [20,21], and that weight loss
can be achieved through multiple approaches [22]. How-
ever, it is unclear whether different diets modeled on
popular weight loss programs which vary markedly in
macronutrient composition differentially affect long
term survival following breast cancer treatment [23-35].
Cross sectional, case control and cohort data is conflict-
ing on fat and carbohydrate intake and breast cancer
risk [36-40], with little data available about dietary
effects on breast cancer survival [41,42]. Moreover, it is
not known whether improvement in biomarkers is pro-
gressive with increasing weight loss. This could result in
very different clinical guidance related to weight loss in
these women.
A number of candidate mechanisms including chronic
inflammation [43-46], cellular oxidation [47-57], and
insulin resistance [58] may explain the link between
energy balance and long term survival following breast
cancer treatment. Biomarkers that relate to these
mechanisms can be measured in blood and urine to
assess potential effects. Although maintaining a healthy
body weight is protective against breast cancer and
weight loss is feasible in post-menopausal breast cancer
survivors [59,60], there are no published studies investi-
gating how fat loss using different dietary macronutrient
compositions (i.e. dietary patterns) influences these
metabolic and hormonal processes. The CHOICE study
seeks to address these questions in an effort to
strengthen the evidence base on modifiable lifestyle fac-
tors, specifically weight loss, and their effects on long
term survival following treatment for breast cancer.
Typically, weight loss plateaus after 6-months and most
weight is regained after 1 to 5 years [61-64], so in addi-
tion to determining whether dietary pattern matters, it
will also become critical to identify ways to promote
weight loss maintenance so that any protection gained is
not transient.
Methods/Design
Study Design
The study, called CHOICE, is a non-randomized, con-
trolled trial in post-menopausal breast cancer survivors
investigating whether an energy restricted dietary pat-
tern, i.e. low carbohydrate, high fat or low fat, high car-
bohydrate, with progressive fat loss during a weight loss
program can alter the likelihood of long term survival
following treatment for breast cancer as reflected in
metabolic and hormonal prognostic biomarkers. A total
of 370 women will be accrued and assigned to one of
the two dietary intervention arms based on eating pre-
ferences or a non-intervention control arm (n = 135 to
each intervention arm, n = 100 to the control arm) and
followed for 6 months as illustrated in Figure 1. Anthro-
pometric measurements are conducted and biomarkers
collected at baseline and 6 months in the control arm,
and monthly in the intervention arms in order to model
the shape of the metabolic and hormonal response
curves.
Study Aims
Primary Aim
The primary aim of the study is to investigate whether
dietary pattern (low carbohydrate or low fat) alters the
patterns of change observed in circulating factors
involved in chronic inflammation, glucose homeostasis,
cellular oxidation, and steroid hormone metabolism dur-
ing progressive loss of body fat. The primary outcome
measure is high sensitivity C-reactive protein. All other
measurements are considered secondary endpoints.
Secondary Aims
1) To explore whether circulating factors associated with
glucose homeostasis, chronic inflammation, and cellular
oxidation display similar patterns of change in response
to progressive fat loss as circulating hormones asso-
ciated with sex steroid metabolism.
2) To determine whether either dietary pattern has a
differential effect on the magnitude or rate of fat loss
and lean tissue changes using a number of devices that
permit ongoing and accurate measurements of body
composition.
Patient Recruitment (Study Setting and Participants)
CHOICE recruits women who have been treated for
breast cancer and attend Rocky Mountain Cancer Cen-
ters in Denver, CO, USA. There are approximately 2000
women enrolled in the clinic. Clinic physicians refer
breast cancer survivors who meet the eligibility criteria.
Participants are also recruited by way of study flyers and
brochures posted throughout the clinical facility. Writ-
t e ni n f o r m e dc o n s e n ti sg i v e nb ys u b j e c t sw h e nt h e y
choose to participate in the program. Following
Sedlacek et al. BMC Cancer 2011, 11:287
http://www.biomedcentral.com/1471-2407/11/287
Page 2 of 10informed consent, participants complete questionnaires
that provide demographic, lifestyle and clinical data
including age, marital status, ethnicity, level of educa-
tion, household income, medical history, medicine and
supplement use, PAR-Q (Physical Activity Readiness
Questionnaire), and emotional well-being. Participants
are also interviewed regarding their dieting, weight
history and readiness for engaging in a comprehensive
weight loss program. This population has a mean age of
60; they are > 98% white and over 50% have post bacca-
laureate training. While not representative of the general
population, this population has proven a very high com-
pliance rate in previous diet-cancer studies conducted
by our laboratory [57,65,66].
1 
Goal 
To determine the effects of opposing dietary patterns during weight loss and the progressive effects of body fat loss 
on surrogate biomarkers of breast cancer recurrence risk.
Question 
How does fat loss by different dietary approaches influence biomarkers of cancer risk (glucose homeostasis, 
inflammation, cellular oxidation, and sex steroid hormone metabolism)? 
Recruitment 
Physicians identify eligible participants, determine whether BMI falls within study range (25-34.9Kg/m
2)
 and write 
study referral. Participants also recruited through study fliers and brochures displayed throughout Cancer Clinic.
Eligible Participants 
Clinic Visits
Endpoint Analysis: Blood and Urine 
Plasma 
Carotinoids,  
IGF-1, IGFBP-3, 
IL-6, CRP, 
Estradiol, TNF-Į. 
SHBG, 
Metabolomics, 
Adiponectin, 
Ghrelin, Leptin 
RNA 
Pathway specific arrays 
DNA 
Genotype 
CPT 
Lymphocytes 
Comet,  
8-hydroxy-
deoxyguanosine 
Anthropometric Measures 
Weight 
Waist to Hip ratio 
Tanita Scale :Bioelectrical Impedance Analysis 
(BIA) 
BOD POD: fat percentage, fat mass, lean muscle 
mass, Resting Metabolic Rate (RMR) 
Pedometer (steps/day) 
Actiheart Heart rate monitor/accelerometer 
Visit 7: 3 Months
Visit 6: 2 Months 
Visit 5: 1 Month 
Visit 4: Meal Planning
Visit 3: Diet Education
Visit 2: Baseline
Visit 1: Consenting
Visit 8: 4 Months
Visit 9: 5 Months
1 Week
1 Week
2 Weeks
2 Weeks
4 Weeks
4 Weeks
4 Weeks
4 Weeks
26 weeks 
Visit 1  
Visit 2
Visit 10
Visit 10:6M o n t h s
4 Weeks
Group session 1 
Group session 2 
Group session 5 
Group session 4 
Screening 
Weight and height verified by Clinical Coordinator; Completed Physician Referral Forms obtained; Eligibility 
Questionnaire administered in person or via telephone; Participants provided with CHOICE consent form and study 
baseline questionnaires.  Baseline appointment date set.  
Assignment by: BMI, tumor grade/stage, treatment type 
Group session 3 
Diet A: High Fat, Low Carbohydrate  Diet B: Low Fat, High Carbohydrate  Control 
Diet Allocation
Clinic Visits 
Serum 
Proteomics, 
Glycated Proteins, 
CA27.29, CEA,  
8-iso-F2Į, 
Creatinine 
Figure 1 Project Overview
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Participants must be referred by their clinical oncologist,
have a pathology report confirming the resected stage of
breast cancer and documentation of the type of systemic
adjuvant therapy, as well as have a BMI in the over-
weight or obese class I range (BMI 25-34.9 kg/m
2). Eli-
gible participants: must be at least 4 months post
radiation or chemotherapy treatment for breast cancer
with no evidence of metastatic disease; must not antici-
pate having surgery over the study duration period;
must not follow a special diet excluding foods or food
groups; have not lost 2 or more kg of body weight over
the month preceding study initiation; must not be tak-
ing pharmaceuticals or supplements for weight manage-
ment; are not being treated for diabetes or blood
glucose control; have no history of eating disorders; do
not have digestive issues that may interfere with dietary
intake, such as irritable bowel syndrome, Crohn’sd i s -
ease, or diverticulitis; have never had surgery involving
constriction or removal of any portion of the gastroin-
testinal tract; have not been diagnosed with hepatitis B,
C, or HIV; do not have implanted electronic devices
such as a pacemaker; and do not use tobacco products.
Participants must also be willing to follow a dietary plan
prescribed for the duration of the study; adhere to
American Cancer Society alcohol guidelines (≤ 1s t a n -
dard drink per day); maintain or increase physical activ-
ity as prescribed to achieve negative energy balance
required for 0.5-1.0 kg weight loss per week; wear a
pedometer and record daily activity; wear an acceler-
ometer/heart rate monitor for 2 weeks during the study
(1 week at the beginning and 1 week at the end of the
study); wear a body or swim suit and cap for body com-
position testing; record food intake daily; and attend up
to ten one-on-one clinic visits and 5 group visits with
seven fasting blood and first-void urine samples in the
intervention groups, or three one-on-one clinic visits
and two fasting blood and first-void urine samples in
the control group over 26 weeks.
Study Groups
Control
Individuals accrued to the non-intervention control group
are given the same information currently provided to all
breast cancer patients about the importance of avoiding
post treatment weight gain, and the health benefits of hav-
ing a BMI in the normal range. Clinical specimens, ques-
tionnaire data, body composition, energy expenditure
from activity and anthropometric data are collected at the
baseline and 6-month (end of study) visits.
Intervention
Intervention participants follow a fully defined diet-phy-
sical activity program designed to create a weekly
negative energy balance equivalent to 3500 kcal, after
adjustments for metabolic adaptations that occur during
extended periods of weight loss. The intervention
groups (135 participants in each arm) receive the same
physical activity protocol promoting published physical
activity guidelines and translated into step recommenda-
tions [67,68], but one of two dietary patterns: low fat or
low carbohydrate.
Dietary Plans
Dietary patterns are composed of opposing fat and car-
bohydrate contents but balanced in protein (Table 1).
Six-weeks of meal plans were designed for five calorie
levels in each diet arm. The meal plans developed
included interchangeable meal options with home-pre-
pared recipes and meal instructions. Supporting materi-
als are provided to facilitate adherence including eating
out and frozen meal options, food brand options consis-
tent with the plan, meal planning tools and shopping
lists. Educational materials were developed based on a
systematic review of strategies supporting weight loss
maintenance, incorporating program components (e.g.
self-monitoring tools) and core competencies reinforcing
weight loss behaviors. These strategies are taught to par-
ticipants through the one-on-one and group sessions in
order to promote high levels of dietary adherence.
Participants are instructed to increase their physical
activity by increasing steps or step equivalents to contri-
bute to a 500 calorie deficit each day in combination
with caloric restriction. Calorie goals are determined
based on resting metabolic rate and energy expenditure
from activity.
Outcome Measures
C-Reactive Protein
Overweight, obesity and insulin resistance are associated
with increases in various cells such as adipocytes, pre-
adipocytes, fibroblasts, and macrophages, which release
adipokines and promote inflammation [69-71]. The
amount of body fat predicts inflammatory C-reactive
protein (CRP) levels among adults [72]. Inflammation
decreases apoptosis, increases breast cancer invasiveness
and decreases prognosis [46,73]. There is convincing
evidence that persistent low grade inflammation as well
Table 1 Mean Proposed Macronutrient Composition by
Diet Group
Low Carbohydrate,
High Fat
High Carbohydrate,
Low Fat
Carbohydrate
(%)
32 64
Fat (%) 48 16
Protein (%) 20 20
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several cancers in humans [44]. Importantly, inflamma-
tion measured via CRP is inversely associated with
breast cancer survival, even independently of BMI
[36,43]. Therefore, CRP is considered the primary
outcome.
Secondary Outcomes
Other Markers of Inflammation
Other inflammatory cytokines that mediate the inflam-
matory response will also be measured, including Inter-
leukin-6 (IL-6) and TNF-a. IL-6 has been correlated
with extent of tumor invasion and metastasis [74].
Glucose Homeostasis
As hyperglycemia and insulin resistance are associated
with an increased risk for breast cancer [75], factors
related to these metabolic processes will be measured
including homeostasis model assessment (HOMA).
HOMA is a method used to quantify insulin resistance
and pancreatic beta cell function and is a calculated
index based on fasting levels of insulin and glucose, giv-
ing an integrated view of glucose utilization. HOMA has
been shown to be associated with increased breast can-
cer incidence [75], and higher breast cancer mortality in
the HEAL study [76]. Fasting insulin alone has also
been shown to be predictive of survival in breast cancer
patients [77]. In addition, insulin-like growth factor-1
(IGF-1), IGF binding protein-3 (IGFBP-3) and the ratio
of IGF-1:IGFBP-3, which provides an estimate of biolo-
gically available IGF-1, a more useful indication of over-
all, longer term control of glucose homeostasis in
relation to breast cancer risk, will be measured [78].
Serum IGF-1 is positively associated with breast cancer
risk, as well as changes in response to caloric restriction
and nutritional alterations [79]. Measuring the effects of
two differing dietary patterns on endogenous production
of IGF-1 will help to further characterize dietary effects
on breast cancer risk.
Cellular Oxidation
The inflammatory response stimulated by obesity and
insulin resistance also increases oxidative stress in the
body [80]. During oxidative stress, byproducts of nucleic
acid metabolism including reactive oxygen species
(ROS) promote cancer development by causing genetic
mutations and DNA damage [55,56,81]. Secondary mea-
sures of cellular oxidation that will be measured include
8-hydroxy-deoxy-guanosine (8-OH-dG) reflecting
defects in DNA repair capacity, and markers of whole
body lipid peroxidation, 8-isoprostane-F2-alpha (8-iso-
PGF2a), which have been shown to play a role in breast
carcinogenesis [49,82,83]. These byproducts of oxidation
are more common in cancerous breast tissue compared
to normal breast tissue [49,55,56], and may also be
altered with reducing energy intake [51,52] and changes
in dietary macronutrient composition [84].
Hormone Metabolism
Overweight postmenopausal women have elevated con-
centrations of circulating estrogens and lower concen-
trations of sex hormone binding globulin (SHBG),
which promotes cell growth, putting them at more than
twice the risk for breast and endometrial cancers, as evi-
denced in the Healthy Eating and Lifestyles (HEAL)
study and the European Prospective Investigation into
Cancer and Nutrition (EPIC) study [12,85,86]. Adipose
tissue exhibits aromatase enzyme activity, converting
androgenic precursors to estradiol and estrone. Estro-
gens may promote tumorigenesis through direct or
indirect induction of free radical-mediated DNA
damage, genetic instability, cell mutations and cell pro-
liferation. Agents such as tamoxifen (selective estrogen
receptor modulators) or the aromatase inhibitors have
been shown to reduce breast cancer incidence and
recurrence [87]. Although warranted, there are currently
no published randomized, controlled studies of the
effect dietary pattern has on estrogens or SHBG and
other candidate mechanisms [88-90]. Secondary hor-
mone metabolism outcomes will include estradiol,
estrone, progesterone, and SHBG.
Adipokines
Adipose tissue produces the hormones adiponectin and
leptin. Low adiponectin, which is an anti-inflammatory
and insulin sensitizer, is associated with increased breast
cancer mortality in breast cancer survivors [76], with
leptin regulating energy balance and metabolism and
playing a role in cell proliferation [91]. These adipo-
kines, as well as plasma ghrelin, will be measured to
provide biological determinants that may also help
explain differences in response to the opposing dietary
patterns.
Anthropometry
Weight, height and waist and hip circumferences are
measured using a standardized protocol. Participants are
in their bathing or body suit for all measurements.
Anthropometry is measured monthly in the intervention
group and at baseline and 6 months in the control
group. Height is measured with a stadiometer. Body cir-
cumferences (waist and hip circumferences) are mea-
sured using a specially manufactured, tension controlled
cloth tape. The participant is instructed to stand erect
with arms relaxed at their sides, feet together and abdo-
men relaxed. Waist circumference is defined as the dia-
meter around the abdomen; it is measured at the
midpoint between the top of the hip bone and the
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end of a normal expiration, with the tape pulled tight
but not compressing the skin. Hip circumference is
measured at the level of the maximum extension of the
buttocks.
Body Fat
BOD POD technology is fundamentally the same as
underwater (hydrostatic) weighing, but uses volumetric
air displacement versus water displacement. All outcome
measures including weight are assessed using validated
and standardized measuring equipment and techniques.
Air displacement plethysmography (BOD POD, Life
Measurement, Inc., Concord, CA) has been shown to
measure changes in body composition in response to
weight change to the same extent as dual x-ray absorp-
tiometry (DEXA), with similar sensitivity [92]. The BOD
POD measures the volume of air a person’sb o d yd i s -
placed while sitting inside a comfortable chamber. By
using air versus water, the BOD POD offers a fast, safe,
and easy-to-use tool for measuring body composition,
without sacrificing accuracy. Since it is based on the
same whole-body measurement principle as hydrostatic
weighing, the BOD POD first measures the subject’s
mass and volume. From these measurements, whole-
body density is determined, and body fat and lean mass
calculated using standardized equations.
Process Measures
Physical Activity
Energy expenditure is measured using accelerometry
and heart rate monitoring technology (Actiheart, CamN-
tech, Inc., Boerne, TX). The Actiheart has been assessed
as being valid and reliable in predicting energy expendi-
ture with walking and running [93,94]. Individuals are
given a plan to increase physical activity to ultimately
meet national guidelines (10,000 steps/d) and facilitate
energy balance tailored to their individual lifestyle and
physical ability.
Dietary Adherence
There is often a large loss to follow up in lifestyle inter-
ventions, especially in longer term studies, which could
cause selection bias due to attrition and over-estimation
of treatment effects [95]. One method to optimize
adherence and retention is to carefully select partici-
p a n t sw h oa r em o r el i k e l yt oc o m p l e t et h es t u d y .T h e
requirements of completing and returning the screening
questionnaires, attendance at the individual meetings,
the necessity of a clinic visit and the successful comple-
tion of the one week food records and other question-
naires are burdensome on potential participants and
result in a lower drop-out rate after assignment to a
study arm. Additionally, study coordinators stress to
potential participants at every screening visit the various
obligations required of them in order to take part in
this very structured diet study. Potential participants
with doubts about participating will be encouraged not
to participate in the study or encouraged to participate
in the control arm until they are more prepared to
make the necessary commitments to the study. The
major method for monitoring adherence to the diet is
by the use of daily food record with physical activity/
step records. Adherence is promoted by 1) ongoing indi-
vidual contacts in person and by telephone, mail, and
email; 2) continuous care/problem solving treatments; 3)
skills training to prevent or cope with setbacks; 4) social
support and social influence strategies and 5) ease of
recording dietary intake by use of meal codes. Addition-
ally, a program of weight management competencies
with ongoing assessment and reinforcement has been
developed to target the gaps in participants’ knowledge
and behaviors related to weight loss. During the screen-
ing process, participants will be assessed for their readi-
ness to change or maintain change, as well as their
general wellbeing or level of depression, which has been
shown to be reciprocally associated with obesity and
predict weight maintenance success [96].
Monitoring Breast Cancer Recurrence
Women with a history of invasive breast cancer are seen
every 3 months for the first 2 years following treatment
at the study site clinic. At each visit, a clinical history is
updated, a physical examination is performed by the
attending oncologist, and serum levels of CA 27.29 and
CEA are determined. The frequency of clinical visits
decreases to every 6 months for the next three years,
a n df o l l o wu po c c u r sa n n u a l ly thereafter. Following a
patient’s enrollment into this study, and for the duration
over which the project is funded, at each of these clini-
cal visits, the relevant disease recurrence data will be
recorded along with height, weight, and body composi-
tion. Blood will also be drawn and banked at each visit
for subsequent hypothesis testing, although such ana-
lyses are beyond the scope of this project.
Data Analysis
All data elements collected will be examined using
descriptive statistics (mean, median, SD, range, percen-
tiles, proportion) and graphical summaries (box plots,
profile plots by time and diet group). Log transforma-
tions will be made before further analysis to stabilize
variances as needed.
The primary hypothesis on C-reactive protein will be
tested using the following ANCOVA model:
Y4 = a + b1Y1 + b2GLYC + e
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months, Y1 is the outcome measure at baseline, and,
GLYC is a 2-level indicator for dietary pattern. This
method of analysis adjusts for any remaining pre-treat-
ment differences between groups (a precaution against
imbalance after diet assignment) and reduces variability
in the data being analyzed [97], thus improving the
power of the test for the main effect of interest, b2.
There will be a wealth of information in the repeated
measures on each subject; the results for all measures
using all available data from all time points will be esti-
mated in a mixed-effects repeated measures model to
assess the slopes and between group differences after
each month of weight loss [98]. The power of this
approach lies in its ability to incorporate all of the avail-
able longitudinal data even in the unbalanced case, that
is, when some of the observations are missing for one
or more individuals. Observations within a person over
time are allowed to be correlated while observations
across individuals are assumed to be independent. These
models will also be used to explore the effects of breast
cancer stage, BMI (a time-varying covariate) and age.
Depending on the appearance of change over time
(seen in the profile plots of each outcome measure by
time and diet) linear or nonlinear mixed models will be
used. If the trend appears to be linear, the following
model for the response vector yi for the ith group will
be used:
yi = Xiβ + Zibi + ei (1)
where bi ~ N (0,D) and ei ~ N (0,Ri) are independent.
Xi is a fixed effects design matrix that includes indica-
tors for diet group (1, 2), assessment time (after each
1.5 kg fat loss, and potential covariates (age) or con-
founders (disease stage, BMI). Zi is a design matrix for
the random effects that allows random subject devia-
tions from the population average response. The mar-
ginal distribution of yi is normal with mean Xi b and
variance Vi = ZiDZ’i + Ri. Parameter estimation in SAS
allows a wide range of specifications for the forms of D
and R, and combines empirical Bayes and restricted
maximum likelihood using the EM algorithm.
If the descriptive graphs suggest a nonlinear model is
appropriate, we will estimate:
yi = f (Xi,β,Zi,bi) + ei (2)
Where bi ~ N (0,D)a n dei ~ N (0,Ri). The marginal
distribution of yi is difficult to find in most cases, but its
mean and variance can be approximated by
f (Xi,β,Zi,0) and Vi = ˜ ZiD ˜ Z’i + Ri
Where ˜ Zi is the partial derivative of f (⋅) with respect
to bi. Parameter estimation in SAS combines a
linearization algorithm, such as Gauss-Newton, and the
method of Laird-Ware for linear mixed models. We will
explore the use of nonlinear models only if it appears
that the response trajectory of Y over time could be fit
well by a smooth nonlinear function. Otherwise, simpler
piece-wise linear mixed models will be fit using Equa-
tion 1 above.
Secondary measures in the 4 families of outcomes will
be assessed using the same statistical methods described
above for the primary measures. That is, ANCOVA
assessment of the measure byd i e tg r o u pa t6m o n t h s
followed by an exploratory analysis with mixed models
using all available data.
Mixed models will also be used to estimate the effects
of fat loss on the 4 families of outcomes. Fat loss and
weight loss will be modeled with the expectation that
differences across diets will be minimal, and success in
weight loss better explained by age, initial BMI, and
usual level of physical activity.
Missing data are expected to be missing at random,
and are unlikely to exceed 5% of all observations. This
assumption will be checked during the initial descriptive
analysis of the data after database lock, and appropriate
sensitivity analyses will be done if there is evidence that
the data are MNAR (missing not-at-random) [99].
Given the nature of the patient population and the
incentives to return for monthly evaluations, we expect
to collect most endpoint measures regardless of compli-
ance. We will accrue 370 subjects with the expectation
of completing at least 135 per diet group and 100 in the
control group, that is, 10% loss to follow-up. Analysis
will be intent-to-treat. All statistical analysis will be
done using SAS version 9 (SAS Institute, Cary, NC).
Limitations
Limitations include the fact that the study is neither
double blinded nor randomized; results may not be gen-
eralizable. The population is free living and as such is
subject to issues of compliance and difficulties with
quantifying dietary intake and physical activity.
Discussion
A number of reports indicate that the prognosis for long
term survival following treatment for breast cancer is
better in women whose body weight for height, assessed
by body mass index (BMI, body weight (kg)/height
(m
2)), is considered to be in the normal range (BMI
18.5 to 24.9) versus women who are overweight (BMI
25.0 to 29.9) or obese BMI ≥ 30.0 [1,4,6,7,9-13,100,101].
Consistent with those reports is the observation that
weight gain post diagnosis increases risk for breast can-
cer recurrence; whereas, weight loss in breast cancer
survivors improves the chances of long term survival
[20,21]. If one takes the available epidemiological and
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why relatively little attention is paid to weight control in
the clinical management of breast cancer survivors post
treatment.
Overweight and obesity are common problems in the
United States, and there is little evidence to indicate
that prevalence is less in breast cancer survivors than in
the population at large, which is estimated to be > 60%
[17]. Obesity has been reported to be the cause for at
least 9% breast cancer cases [102]. Thus, given that the
majority of breast cancer survivors have excess weight
as a risk factor, the population at risk is large. However,
a number of challenges are faced by the physician. They
include issues such as initiating a conversation about
weight loss while recognizing the sensitivity of the sub-
ject and time constraints of office visits, which do not
allow sufficient time to address the complexity of indivi-
dual weight management issues, including the knowl-
edge and behavioral gaps related to diet and weight loss.
Moreover, there may be hesitation to emphasize weight
loss given the recognized 95% long term failure rates of
most weight control efforts, making this information a
lower priority during the office visit [22,103-110]. Addi-
tionally, due to lack of knowledge about the subject
matter, basic questions such as, ‘How should weight loss
be achieved?’ and, ‘How much weight loss will provide
benefit?’ cannot be answered with confidence. While
many studies have examined differences in effectiveness
among various approaches to weight loss [22,103-110],
relatively few studies have been conducted in a free liv-
ing population of breast cancer survivors in the private
practice setting. This study will provide information that
can be used to answer patient’s questions about the
effects of dietary pattern and magnitude of weight loss
on long term survival following breast cancer treatment.
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